Journal article
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial
Abstract
AIMS: It is unknown whether Asian and non-Asian patients with atherosclerotic vascular disease derive similar benefits from long-term antithrombotic therapy.
METHODS AND RESULTS: In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2.5 mg b.i.d. plus aspirin 100 mg o.d. were compared with …
Authors
Hori M; Zhu J; Liang Y; Bhatt DL; Bosch J; Connolly SJ; Fox KAA; Maggioni A; Yusuf S; Eikelboom JW
Journal
European Heart Journal, Vol. 43, No. 37, pp. 3542–3552
Publisher
Oxford University Press (OUP)
Publication Date
October 7, 2022
DOI
10.1093/eurheartj/ehac309
ISSN
0195-668X